Bryan Garnier - MEDARTIS (MEDA) MEDARTIS: Medartis post extremely strong 1H20, raises guidance | BUY | CHF80(-20%)

Report

Bryan Garnier

Dylan Van Haaften

MEDARTIS: Medartis post extremely strong 1H20, raises guidance | BUY | CHF80(-20%)

MEDARTIS - BUY | CHF80(-20%)
Medartis post extremely strong 1H20, raises guidance

Medartis posts top line 5% beat, raises guidance to +20% CER for FY20e
We see multiple further avenues of share price performance
We re-iterate our BUY, thesis more attractive post 1H21

17/08/2021 1 EN

Underlying

MEDARTIS

See profile

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Dylan Van Haaften

Other Reports on these Companies

Bryan Garnier

MEDARTIS: 1H in-line, but murkier outlook and guidance cut for remainder ‘22 | BUY | CHF175

MEDARTIS - BUY | CHF175 1H in-line, but murkier outlook and guidance cut for remainder ‘22 1H headline broadly in line, but some pressure on ‘22e 2H forecasts in our view Re-iterate Buy, CHF 175 TP as long term Upper and Lower extremities thesis is intact

August 16, 2022 August 16, 2022 1 EN

Bryan Garnier

MEDARTIS: What’s Next(remity)? Increase TP to CHF175 | BUY Top Picks | CHF175 VS. CHF155 (+28%)

MEDARTIS - BUY Top Picks | CHF175 VS. CHF155 (+28%) What’s Next(remity)? Increase TP to CHF175 We increase our TP to CHF175 from CHF155, keep our BUY and retain Medartis on our Top Picks list as we believe the Nextremity acquisition is on a ‘21e-‘25e basis highly accretive (see next page). Furthermore, we believe guidance of ~20% CER growth and ~18% (ex.- Nextremity; 12%-13% inc.) underlying EBITDA margins are attainable, which has been reinforced on the NDRs we have had with management this week. We believe trends (post-COVID trauma/elective surgeries/ inflation) are all largely supportive f...

March 10, 2022 March 10, 2022 1 EN

Bryan Garnier

MEDARTIS: Strong organic performance and a new acquisition | BUY Top Picks | CHF155(+12%)

MEDARTIS - BUY Top Picks | CHF155(+12%) Strong organic performance and a new acquisition This morning Medartis announced FY results which were a beat on organic growth and announced a new acquisition (Nextremity). Medartis has also issued an outlook of sales growth around 20% CER and an improvement of EBITDA margins by 1% point (~18.2% EBITDA ’22) excluding the acquisition. The newly announced acquisition is largely unknown but is expected to be accretive on a Mid-term basis. The company will host a conference call at 10:00 CET.

March 7, 2022 March 7, 2022 1 EN

ONWARD: from brainGPT to ARC-BCI – fireside chat with the founders

Yesterday, we hosted an exclusive fireside chat at our Paris HQ with ONWARD's co-founders, Dr. Grégoire Courtine and Dr. Jocelyne Bloch, accompanied by institutional investors, to learn about the professional endeavours that led them to jump from researchers to entrepreneurs, with a special deep-di

12h / 11m 12h / 11m 1 EN

Mahaut Arnaud ... (+3)

Mahaut Arnaud
Paul de Froment
Thomas Mordelle

Avantium: joint-development progress in textiles

Yesterday, Avantium announced the successful development of a PEF-based spacer fabric in collaboration with partners Auping, Muller Textiles, Antex and Monosuisse. This breathable, cushioning 3D material marks a step forward for this partnership, ongoing since 2024, aiming to create PEF-based yarns

12h / 17m 12h / 17m 1 EN

Oscar Haffen Lamm

Oscar Haffen Lamm

Egetis: Article highlights Emcitate's broad efficacy in MCT8 deficiency

A recent publication in Nature Communications (Groeneweg, van Geest et al. 2025) highlights the broad therapeutic applicability of Emcitate across the heterogeneity of the MCT8 deficient target group and supporting its uniform treatment eligibility across a genetically diverse patient population. I

12h / 23m 12h / 23m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

MEDARTIS: Medartis post extremely strong 1H20, raises guidance | BUY | CHF80(-20%)

MEDARTIS: 1H in-line, but murkier outlook and guidance cut for remainder ‘22 | BUY | CHF175

MEDARTIS: What’s Next(remity)? Increase TP to CHF175 | BUY Top Picks | CHF175 VS. CHF155 (+28%)

MEDARTIS: Strong organic performance and a new acquisition | BUY Top Picks | CHF155(+12%)

ONWARD: from brainGPT to ARC-BCI – fireside chat with the founders

Avantium: joint-development progress in textiles

Egetis: Article highlights Emcitate's broad efficacy in MCT8 deficiency

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe